Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 7/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.37 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29523288 | 1.00 | ESR2 (0.43) | ESR2NR1H2MKNK1ADORA1DPP4 | |
| SCHEMBL19667710 | 0.87 | ESR2 (0.46) | ESR2NR1H2MKNK1ADORA1DPP4 | |
| SCHEMBL29523461 | 0.87 | ESR2 (0.46) | ESR2NR1H2MKNK1ADORA1DPP4 | |
| SCHEMBL23897065 | 0.86 | ESR2 (0.46) | ESR2NR1H2MKNK1ADORA1DPP4 | |
| SCHEMBL29236998 | 0.82 | ABHD6 (0.32) | ABHD6 | |
| SCHEMBL29523494 | 0.80 | ESR2 (0.38) | ESR2NR1H2MKNK1ADORA1DPP4 | |
| SCHEMBL21682925 | 0.80 | ESR2 (0.38) | ESR2NR1H2MKNK1ADORA1DPP4 | |
| SCHEMBL19679219 | 0.80 | ESR2 (0.48) | ESR2NR1H2MKNK1ADORA1DPP4 | |
| SCHEMBL22787765 | 0.79 | ESR2 (0.38) | ESR2NR1H2MKNK1ADORA1DPP4 | |
| SCHEMBL29522675 | 0.79 | ESR2 (0.38) | ESR2NR1H2MKNK1ADORA1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391695-B2 | PRMT5 inhibitors | LUPIN LIMITED (IN) | 2025-08-19 | — | — | US | disclosed |
| EP-3980417-B1 | PRMT5 INHIBITORS | LUPIN LTD (IN) | 2023-09-27 | — | — | EP | disclosed |
| US-20220315589-A1 | PRMT5 INHIBITORS | LUPIN LIMITED (IN) | 2022-10-06 | — | — | US | disclosed |
| EP-3980417-A1 | PRMT5 INHIBITORS | Lupin Limited (IN) | 2022-04-13 | — | — | EP | disclosed |
| WO-2020250123-A1 | PRMT5 INHIBITORS | LUPIN LIMITED (IN) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315589-A1 | PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | ESR2 2967/4885NR1H2 1646/4885MKNK1 618/4885 |
| US-12391695-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | ESR2 2967/4885NR1H2 1646/4885MKNK1 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.